Alexion Pharmaceuticals Inc (ALXN)

NASDAQ
182.50
0.00(0.00%)
  • Volume:
    0
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    180.13 - 182.67

ALXN Overview

Prev. Close
182.5
Day's Range
180.13-182.67
Revenue
6.26B
Open
181.04
52 wk Range
99.91-187.45
EPS
3.05
Volume
0
Market Cap
36.08B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
4,279,854
P/E Ratio
59.91
Beta
1.25
1-Year Change
48.68%
Shares Outstanding
199,613,272
Next Earnings Date
-
What is your sentiment on Alexion Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.

Alexion Pharmaceuticals Inc Company Profile

Employees
3837

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. The company was incorporated in 1992 and is based in Boston, Massachusetts with an additional office in Switzerland. As of July 21, 2021, Alexion Pharmaceuticals, Inc. operates as a subsidiary of AstraZeneca PLC.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyBuyBuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong SellStrong Buy
SummaryStrong BuyStrong BuyStrong BuyNeutralStrong Buy
  • Give the anti-corona spray from marinomed-biotech some VC and invest in a pharma company which is heading to the moon:https://www.investing.com/equities/marinomed-biotech-agStudies are proving that the patented method of marinomed prevents infection with all Corona varietis including mutants. It also prevents other virus infections. They have many patents.  Do some good and get rich
    1
    • ATVI, Nio, Li and Fcel will be very good shares to buy and hold.. 30% to 60% gain gradually soon..
      1
      • Currently this should trading st about 166-167, due to the buyout. Seems like market here is off by in ballbark of 10.
        0
        • market is pricing risk of deal not going through, thats why astrazenca plummeted today
          0
        • Ok, ty, i thought as much
          0
        • Gerard Oliva Even if the deal doesn't go throught, alexion is still a compagny to buy
          0
      • Shouldnt it be trading at around 167 atm. ?
        0
        • Candy Man AZN?
          0
        • Astrazeneca
          0
        • Candy Man Ya brain farted lol, was having lunch
          0
      • still needs to go to atleast177 to represent the new marketcap of 39 bill after the sale.
        0
        • TUSK double the price very soon..Very low volume.. Easy to jump.. Don't miss it.. Good luck guys..
          1
          • why is this stock rising if it was sold
            1
            • Astra buys Alexion for a share price of $175
              0
            • only 60 is money rest AZN shares. Deal can go bust also and AZN share price is down 5pros so pris is buying price is down like 3pros. If deal goes sauer Alexion will go under original price fast and hard.
              0
          • AstraZeneca is buying this, what is next? (read article)
            0
            • Long tp 165
              0
            • they buy it at share price around 175$, shareholders get AstraZeneca shares and a premium too
              0
          • Cocrystal Pharma, Inc. (COCP), up 45%
            0
            • seems extremely undervalued and yet no takers? can anyone explain?
              1
              • if you check the historical fundamentals I agree, it seems to be very undervalued. BUT the earnings depends strongly of a very expensive drug for a rare disease and concurrents have fund a less expensive efficacious drug for the same disease.
                3
              • You were right. Its 31 aug today and the price just increased by alot.
                2
              • Waiting for low $90s, may be another shot there. It's not about what you think is undervalued, it's about what market thinks.
                1
            • what is good for week position?
              0
              • buy for ALXN?
                0
                • strong balance sheet
                  0
                  • what's going on?
                    0
                    • Nobody knows actually
                      0
                  • trash
                    3
                    • why?
                      0
                  • i think ALXN is one of the best in its industry
                    0
                    • 5
                      0
                      • Strong buy
                        0
                        • 현수 김 amazing financials and strong growth in years. Stock is one of the most undervalued on the entire market
                          0
                        • 현수 김 analysts average 12 months target price: 144$ (44% up)
                          0
                        • cool. Are you gonna sit in this comment section for 12 months?
                          1
                      • Any real thoughts on Alexion
                        0
                        • I got a deep thoughts but guess we cant upload POC here
                          0
                        • point of contacy
                          0
                        • t*
                          0
                      • Simply got into sh... company.
                        1
                        • They lost their patent in 2017 for the eculizumab or soliris, the drug which is now being tested.
                          0
                          • Will these guys launch covid-19 vaccine attempt announcement?
                            1
                            • Run away from here !
                              4
                              • idling at 114.40
                                0
                                • What happened? Down 6.6%.
                                  0
                                  • a lot competitor getting close
                                    1
                                Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.